

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-69. (Canceled)

70. **(Currently Amended)** A method for making a genetically stable cell that produces a therapeutically hypermutated immunogen comprising the steps of:
introducing into a cell that expresses a gene encoding a preselected immunogen *in vitro* a polynucleotide comprising a dominant negative allele of ~~a mismatch repair gene, wherein said dominant negative allele is a truncation mutant of a~~ PMS2,
selecting cells that comprise a mutation in said gene encoding said preselected immunogen, wherein the mutation results in enhanced antigenicity or immunogenicity of said immunogen;
and expressing a polynucleotide sequence of said mutated gene encoding said preselected immunogen in a genetically stable cell.

71. (Canceled)

72. (Previously Presented) The method of claim 70 wherein said introduction of said polynucleotide is in the presence of at least one DNA mutagen.

73. **(Currently Amended)** The method of claim 70 wherein the PMS2~~mismatch repair gene~~ is human PMS2.

74. (Previously Presented) The method of claim 73 wherein the allele comprises a truncation mutation at codon 134.

75. (Previously Presented) The method of claim 74 wherein the truncation mutation is a thymidine at nucleotide 424 of wild-type PMS2.

76. (Previously Presented) The method of claim 70 wherein said step of selecting cells is based on a determination that the polynucleotide encoding said preselected immunogen

DOCKET NO.: MOR-0277

PATENT

Application No.: 10/813,502

Office Action Dated: December 18, 2006

comprises a mutation as compared to the polynucleotide of a parental cell prior to introduction of said dominant negative allele of a PMS2 mismatch repair gene

77. (Previously Presented) A homogeneous culture of cells produced by the method of claim 70.